We do not sell Korlym internationally. The preferred treatment is surgery, which, if successful, can cure the disease. Forty-four percent of patients in Korlym's pivotal trial experienced hypokalemia. In other cancers, cortisol stimulates genes that retard cellular apoptosis. Relacorilant in Patients with Solid Tumors. The primary endpoint in both trials is reduction in body weight. ICON plc is helping us conduct our GRACE and GRADIENT trials. See "Part I, Item 3, Legal Proceedings. In the EU, Isturisa is also approved as a treatment for Cushing's syndrome. This license also covers related applications in countries around the world. Foreign counterparts of five of these patents have issued in Europe. A sixth group of "general risks" lists risks that affect our business as a whole. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any stage of drug development. Such capital may not be available on acceptable terms or at all. Compliance with these requirements is complex and costly. Since 2012, a medication owned by the Italian pharmaceutical company Recordati-S.p. Clinical development is expensive, lengthy and often unsuccessful. To date, we have relied on a small management team. We may also choose to raise funds for strategic reasons. Third parties may allege that our patents infringe their rights. We do not have liability insurance for patent infringement. The effect on our business of the COVID-19 pandemic is difficult to estimate. We rely heavily on information technology systems to conduct our business. Changes in federal, state and local tax laws may reduce our net earnings. Obtaining regulatory approval of a drug is difficult, uncertain, lengthy and expensive.